A Critique in Need of Critique

Public Health Ethics 3 (2):178-185 (2009)
Is it really necessary to add something like the Health Impact Fund to the existing global patent system? We can divide this question into two parts. First, is there something seriously wrong with the status quo and, if so, what exactly is it? Second, how do we best go about solving the problem; that is, how does the design of the reform proposal address the flaws in the status quo? Jorn Sonderholm, in his critique of the Health Impact Fund, or HIF, raises both of these issues. These criticisms afford us the opportunity to reaffirm our commitment to ameliorating glaring problems with the current system for incentivizing R&D for essential medicines, and to clarify why we believe the HIF is exactly what the world needs
Keywords No keywords specified (fix it)
Categories (categorize this paper)
Reprint years 2010
DOI 10.1093/phe/php037
 Save to my reading list
Follow the author(s)
My bibliography
Export citation
Find it on Scholar
Edit this record
Mark as duplicate
Revision history Request removal from index
Download options
PhilPapers Archive

Upload a copy of this paper     Check publisher's policy on self-archival     Papers currently archived: 24,422
External links
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library
References found in this work BETA

Add more references

Citations of this work BETA
Tom Andreassen (2015). Patent Funded Access to Medicines. Developing World Bioethics 15 (3):152-161.

Add more citations

Similar books and articles

Monthly downloads

Added to index


Total downloads

22 ( #213,849 of 1,924,770 )

Recent downloads (6 months)

2 ( #308,315 of 1,924,770 )

How can I increase my downloads?

My notes
Sign in to use this feature

Start a new thread
There  are no threads in this forum
Nothing in this forum yet.